We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Altered Gut Flora Could Indicate Parkinson's

By LabMedica International staff writers
Posted on 12 Sep 2017
In search of a early-diagnostic biomarker for Parkinson’s disease, researchers have found that specific changes in the gut microbiota could help identify the disease in its early stages, before clinical symptoms appear.

By the time Parkinson's disease manifests as the typical motor dysfunctions such as tremors or muscle rigidity, portions of the brain have already been irreversibly destroyed; the disease will have often begun already decades earlier. More...
In search of an early portent of the disease, researchers led by Paul Wilmes, professor at University of Luxembourg (Esch-sur-Alzette, Luxembourg) may now have found one in the gut: they have shown that the bacterial community in the gut of Parkinson's patients differs from that of healthy people even at a very early stage of the disease.

Experts have long been discussing the notion that Parkinson's disease originates far outside the brain. According to the "dual hit" hypothesis, a hitherto unknown pathogen intrudes into the body through two ports of entry: the nose or the gastrointestinal tract. Once there, it sets a pathological process in motion, above all the misfolding of the protein alpha-synuclein, whose function is as yet largely unknown. Among other things, it is presumed to be involved in the excretion of messengers such as dopamine. The misfolding of this protein could propagate through the nerve pathways, where - decades later - it produces the typical clumping in the dopaminergic cells, Lewy bodies, that are characteristic of Parkinson's. Ultimately, nerve cells start to die off and the typical symptoms of Parkinson's disease appear.

The researchers led by Prof. Wilmes, together with physicians Prof. Brit Mollenhauer and Prof. Wolfgang Oertel and their teams in Göttingen, Kassel, and Marburg, explored the question of whether the early events in the course of the disease also change the microbiome at the two likely ports of entry. They took samples from the nose and gut of 76 Parkinson's patients and 78 healthy control people (who are taking part in a long-term study). They also examined the microbiome of 21 subjects diagnosed with Idiopathic Rapid-Eye-Movement Sleep Behaviour Disorder (iRBD), because iRBD patients have a greatly elevated risk of developing Parkinson's disease later in life.

The results showed that the gut bacterial community differed considerably between all three groups. "Parkinson's patients could be differentiated from healthy controls by their respective gut bacteria," explained first-author Dr. Anna Heintz-Buschart. And the majority of the differential bacteria showed similar trends in the iRBD group. For example, certain bacterua were more prevalent in one group while the count was lower in others. In the samples from the subjects' nasal cavities, however, the researchers found no such differences. Certain gut microbes were also associated with non-motor Parkinson's symptoms, for example depression.

"We hope that, by comparing the groups, we will learn to better understand the role of the microbiome in the process of the disease and to find out what changes occur and when," Paul Wilmes explained, "This might deliver new starting points for early treatment of the disease. It would also be essential knowledge for one day being able to use the absence or presence of certain bacteria as a biomarker for early detection of the disease."

The study, by Heintz-Buschart A et al, was published August 26, 2017, in the journal Movement Disorders.

Related Links:
University of Luxembourg



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Rheumatoid Factors (RF) Test
Rheumatoid Factors (RF)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.